Inge Marie Svane

List of Publications by Year
in descending order

176	8,997	53794 45	56724 83
papers	citations	h-index	g-index

184	184	184	12403
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Epigenetic therapy in combination with a multi-epitope cancer vaccine targeting shared tumor antigens for high-risk myelodysplastic syndromeÂ-Âa phase I clinical trial. Cancer Immunology, Immunotherapy, 2022, 71, 433-444.	4.2	8
2	Cardiotoxicity in metastatic melanoma patients treated with BRAF and MEK inhibitors in a real-world setting. Acta OncolÃ³gica, 2022, 61, 45-51.	1.8	3
3	Neoantigen-reactive CD8+ T cells affect clinical outcome of adoptive cell therapy with tumor-infiltrating lymphocytes in melanoma. Journal of Clinical Investigation, 2022, 132, .	8.2	54
4	Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvant, CAFÂ®09b, in patients with metastatic melanoma. OncoImmunology, 2022, 11, 2023255.	4.6	18
5	Clinical value of routine [18F]2â€fluoroâ€2â€deoxyâ€<scp>d</scp>â€glucose positron emission tomography scans as a decision tool for early immunotherapy discontinuation in advanced melanoma. International Journal of Cancer, 2022, 150, 1870-1878.	5.1	5
6	Peptide vaccination activating Galectin-3-specific T cells offers a novel means to target Galectin-3-expressing cells in the tumor microenvironment. OncoImmunology, 2022, 11, 2026020.	4.6	9
7	Randomized phase 2 study of nivolumab with or without ipilimumab in combination with stereotactic body radiotherapy in patients with refractory metastatic pancreatic cancer (CHECKPAC).. Journal of Clinical Oncology, 2022, 40, 554-554.	1.6	1
8	Highly efficient PD-1-targeted CRISPR-Cas9 for tumor-infiltrating lymphocyte-based adoptive TÂcell therapy. Molecular Therapy - Oncolytics, 2022, 24, 417-428.	4.4	19
9	B Cells and Tertiary Lymphoid Structures: Friends or Foes in Cancer Immunotherapy?. Clinical Cancer Research, 2022, 28, 1751-1758.	7.0	39
10	Fibrotic activity quantified in serum by measurements of type III collagen pro-peptides can be used for prognosis across different solid tumor types. Cellular and Molecular Life Sciences, 2022, 79, 204.	5.4	12
11	Immune Checkpoint Inhibitor Treatment and Ophthalmologist Consultations in Patients with Malignant Melanoma or Lung Cancerâ€"A Nationwide Cohort Study. Cancers, 2022, 14, 49.	3.7	2
12	Tumor-infiltrating lymphocytes for adoptive cell therapy: recent advances, challenges, and future directions. Expert Opinion on Biological Therapy, 2022, 22, 627-641.	3.1	19
13	Randomized Phase II Study of Nivolumab With or Without Ipilimumab Combined With Stereotactic Body Radiotherapy for Refractory Metastatic Pancreatic Cancer (CheckPAC). Journal of Clinical Oncology, 2022, 40, 3180-3189.	1.6	29
14	Pembrolizumab (pembro) plus dabrafenib (dab) and trametinib (tram) in BRAF^{V600E/K}-mutant melanoma: Long-term follow-up of KEYNOTE-022 parts 1, 2, and 3.. Journal of Clinical Oncology, 2022, 40, 9516-9516.	1.6	6
15	Perspectives in Immunotherapy: meeting report from the Immunotherapy Bridge, December 1stâ€"2nd, 2021. Journal of Translational Medicine, 2022, 20, .	4.4	4
16	LTX-315 and adoptive cell therapy using tumor-infiltrating lymphocytes in patients with metastatic soft tissue sarcoma.. Journal of Clinical Oncology, 2022, 40, 11567-11567.	1.6	4
17	EMRseq: Registry-based outcome analysis on 1,000 patients with BRAF V600â€"mutated metastatic melanoma in Europe treated with either immune checkpoint or BRAF-/MEK inhibition.. Journal of Clinical Oncology, 2022, 40, 9540-9540.	1.6	5
18	Indirect assessment of tumor-infiltrating lymphocyte activity in serum for predicting outcome in patients with glioblastoma treated with immunotherapy in the recurrent setting.. Journal of Clinical Oncology, 2022, 40, 2059-2059.	1.6	0

#	Article	IF	Citations
19	Abstract CT535: High clinical efficacy in poor prognosis patients with metastatic melanoma treated with an IDO/PD-L1 peptide vaccine in combination with nivolumab. Cancer Research, 2022, 82, CT535-CT535.	0.9	1
20	Randomized phase 3 trial of IO102-IO103 plus pembrolizumab versus pembrolizumab alone in patients with previously untreated, unresectable, or metastatic melanoma.. Journal of Clinical Oncology, 2022, 40, TPS9589-TPS9589.	1.6	0
21	First-in-human clinical trial of an oncolytic adenovirus armed with TNFa and IL-2 in patients with advanced melanoma receiving adoptive cell transfer of tumor-infiltrating lymphocytes.. Journal of Clinical Oncology, 2022, 40, TPS9590-TPS9590.	1.6	1
22	The effects of targeted immune-regulatory strategies on tumor-specific T-cell responses in vitro. Cancer Immunology, Immunotherapy, 2021, 70, 1771-1776.	4.2	8
23	The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study. European Heart Journal, 2021, 42, 1621-1631.	2.2	102
24	An immunogenic first-in-human immune modulatory vaccine with PD-L1 and PD-L2 peptides is feasible and shows early signs of efficacy in follicular lymphoma. OncoImmunology, 2021, 10, .	4.6	5
25	Cytotoxic T cells isolated from healthy donors and cancer patients kill TGFÎ²-expressing cancer cells in a TGFÎ²-dependent manner. Cellular and Molecular Immunology, 2021, 18, 415-426.	10.5	10
26	Therapeutic Cancer Vaccination With a Peptide Derived From the Calreticulin Exon 9 Mutations Induces Strong Cellular Immune Responses in Patients With CALR-Mutant Chronic Myeloproliferative Neoplasms. Frontiers in Oncology, 2021, 11, 637420.	2.8	29
27	Immune check point inhibitors are associated with a spectrum of cardiac events in patients with cancer. European Heart Journal, 2021, 42, 1636-1636.	2.2	4
28	Vaccination against PD-L1 with IO103 a Novel Immune Modulatory Vaccine in Basal Cell Carcinoma: A Phase IIa Study. Cancers, 2021, 13, 911.	3.7	7
29	Immune Cell Profiling of Peripheral Blood as Signature for Response During Checkpoint Inhibition Across Cancer Types. Frontiers in Oncology, 2021, 11, 558248.	2.8	17
30	Bone marrow toxicity and immune reconstitution in melanoma and non-melanoma solid cancer patients after non-myeloablative conditioning with chemotherapy and checkpoint inhibition. Cytotherapy, 2021, 23, 724-729.	0.7	5
31	Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase 3 trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma.. Journal of Clinical Oncology, 2021, 39, 9500-9500.	1.6	4
32	Clinical efficacy of T-cell therapy after short-term BRAF-inhibitor priming in patients with checkpoint inhibitor-resistant metastatic melanoma. , 2021, 9, e002703.		9
33	The capacity of CD4+ VÎ³9VÎ´2 T cells to kill cancer cells correlates with co-expression of CD56. Cytotherapy, 2021, 23, 582-589.	0.7	6
34	Transcriptomic signatures of tumors undergoing T cell attack. Cancer Immunology, Immunotherapy, 2021, , 1.	4.2	6
35	ACT Up TIL Now: The Evolution of Tumor-Infiltrating Lymphocytes in Adoptive Cell Therapy for the Treatment of Solid Tumors. Immuno, 2021, 1, 194-211.	1.5	9
36	The Danish metastatic melanoma database (DAMMED): A nation-wide platform for quality assurance and research in real-world data on medical therapy in Danish melanoma patients. Cancer Epidemiology, 2021, 73, 101943.	1.9	21

#	Article	IF	Citations
37	Lynch syndrome-associated epithelial ovarian cancer and its immunological profile. Gynecologic Oncology, 2021, 162, 686-693.	1.4	10
38	Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types. , 2021, 9, e003499.		23
39	Rapid Identification of the Tumor-Specific Reactive TIL Repertoire via Combined Detection of CD137, TNF, and IFNÎ³, Following Recognition of Autologous Tumor-Antigens. Frontiers in Immunology, 2021, 12, 705422.	4.8	10
40	Laser Immunotherapy: A Potential Treatment Modality for Keratinocyte Carcinoma. Cancers, 2021, 13, 5405.	3.7	6
41	Comparison of Efficacy in Patients with Metastatic Melanoma Treated with Ipilimumab and Nivolumab Who Did or Did Not Discontinue Treatment Due to Immune-Related Adverse Events: A Real-World Data Study. Cancers, 2021, 13, 5550.	3.7	4
42	Myeloid antigen-presenting cell niches sustain antitumor TÂcells and license PD-1 blockade via CD28 costimulation. Cancer Cell, 2021, 39, 1623-1642.e20.	16.8	64
43	CTIM-22. NIVOLUMAB AND BEVACIZUMAB FOR RECURRENT GLIOBLASTOMA; T-CELL REACTIVITY AGAINST AUTOLOGOUS TUMOR CELLS. Neuro-Oncology, 2021, 23, vi54-vi55.	1.2	0
44	CTIM-23. EVIDENCE OF T CELL ACTIVATION AND INTRATUMORAL NIVOLUMAB-PRESENCE IN GLIOBLASTOMA PATIENTS TREATED WITH NIVOLUMAB AND BEVACIZUMAB. Neuro-Oncology, 2021, 23, vi55-vi55.	1.2	0
45	Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma. European Journal of Cancer, 2021, 158, 156-168.	2.8	19
46	A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma. Nature Medicine, 2021, 27, 2212-2223.	30.7	88
47	Common phenotypic dynamics of tumor-infiltrating lymphocytes across different histologies upon checkpoint inhibition: impact on clinical outcome. Cytotherapy, 2020, 22, 204-213.	0.7	9
48	Qualitative Analysis of Tumor-Infiltrating Lymphocytes across Human Tumor Types Reveals a Higher Proportion of Bystander CD8+ T Cells in Non-Melanoma Cancers Compared to Melanoma. Cancers, 2020, 12, 3344.	3.7	19
49	Genetic Biomarkers in Melanoma of the Ocular Region: What the Medical Oncologist Should Know. International Journal of Molecular Sciences, 2020, 21, 5231.	4.1	15
50	Escape from nonsense-mediated decay associates with anti-tumor immunogenicity. Nature Communications, 2020, 11, 3800.	12.8	61
51	Future role for adoptive T-cell therapy in checkpoint inhibitor-resistant metastatic melanoma. , 2020, 8, e000668.		31
52	Improved Progression-Free Long-Term Survival of a Nation-Wide Patient Population with Metastatic Melanoma. Cancers, 2020, 12, 2591.	3.7	8
53	Changes in the Tumor Immune Microenvironment during Disease Progression in Patients with Ovarian Cancer. Cancers, 2020, 12, 3828.	3.7	19
54	Peptide Vaccination Against PD-L1 With IO103 a Novel Immune Modulatory Vaccine in Multiple Myeloma: A Phase I First-in-Human Trial. Frontiers in Immunology, 2020, 11, 595035.	4.8	17

#	Article	IF	Citations
55	In vitro 4-1BB stimulation promotes expansion of CD8+ tumor-infiltrating lymphocytes from various sarcoma subtypes. Cancer Immunology, Immunotherapy, 2020, 69, 2179-2191.	4.2	16
56	Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma. , 2020, 8, e000391.		39
57	CTLA-4 blockade boosts the expansion of tumor-reactive CD8+ tumor-infiltrating lymphocytes in ovarian cancer. Scientific Reports, 2020, 10, 3914.	3.3	50
58	The metabolic enzyme arginase-2 is a potential target for novel immune modulatory vaccines. OncoImmunology, 2020, 9, 1771142.	4.6	18
59	T-Cell Gene Therapy in Cancer Immunotherapy: Why It Is No Longer Just CARs on The Road. Cells, 2020, 9, 1588.	4.1	20
60	Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature, 2020, 577, 561-565.	27.8	1,209
61	Genome-wide CRISPRâ€“Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1. Nature Immunology, 2020, 21, 178-185.	14.5	186
62	Characterization of risk factors and efficacy of medical management of immune-related hepatotoxicity in real-world patients with metastatic melanoma treated with immune checkpoint inhibitors. European Journal of Cancer, 2020, 130, 211-218.	2.8	23
63	Cutaneous adverse reactions to antiâ€“PD-1 treatmentâ€”A systematic review. Journal of the American Academy of Dermatology, 2020, 83, 1415-1424.	1.2	29
64	Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations. Frontiers in Immunology, 2020, 11, 373.	4.8	27
65	KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma. , 2020, 8, e001806.		110
66	Adoptive cell therapy in combination with checkpoint inhibitors in ovarian cancer. Oncotarget, 2020, 11, 2092-2105.	1.8	64
67	Granzyme B Degraded Type IV Collagen Products in Serum Identify Melanoma Patients Responding to Immune Checkpoint Blockade. Cancers, 2020, 12, 2786.	3.7	32
68	Therapeutic Cancer Vaccination Targeting Shared Tumor Associated Antigens in Combination with Azacitidine for High Risk Myelodysplastic Syndrome - a Phase I Clinical Trial. Blood, 2020, 136, 23-24.	1.4	2
69	Empty peptide-receptive MHC class I molecules for efficient detection of antigen-specific T cells. Science Immunology, 2019, 4, .	11.9	64
70	Bâ€¢cell frequencies and immunoregulatory phenotypes in myeloproliferative neoplasms: Influence of ruxolitinib, interferonâ€Î±2, or combination treatment. European Journal of Haematology, 2019, 103, 351-361.	2.2	6
71	Real-World Impact of Immune Checkpoint Inhibitors in Metastatic Uveal Melanoma. Cancers, 2019, 11, 1489.	3.7	37
72	Arginase-1-based vaccination against the tumor microenvironment: the identification of an optimal T-cell epitope. Cancer Immunology, Immunotherapy, 2019, 68, 1901-1907.	4.2	16

#	Article	IF	Citations
73	Age favoured overall survival in a large population-based Danish patient cohort treated with anti-PD1 immune checkpoint inhibitor for metastatic melanoma. European Journal of Cancer, 2019, 119, 122-131.	2.8	27
74	Tumour-reactive T cell subsets in the microenvironment of ovarian cancer. British Journal of Cancer, 2019, 120, 424-434.	6.4	44
75	Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma. Nature Medicine, 2019, 25, 941-946.	30.7	256
76	High-dose interleukin-2 and interferon as first-line immunotherapy for metastatic melanoma: long-term follow-up in a large unselected Danish patient cohort. European Journal of Cancer, 2019, 115, 61-67.	2.8	11
77	Peripheral memory T cells specific for Arginase-1. Cellular and Molecular Immunology, 2019, 16, 718-719.	10.5	13
78	Collagen density regulates the activity of tumor-infiltrating T cells. , 2019, 7, 68.		239
79	Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial. Journal of Clinical Oncology, 2019, 37, 867-875.	1.6	258
80	Peptide Super-Agonist Enhances T-Cell Responses to Melanoma. Frontiers in Immunology, 2019, 10, 319.	4.8	18
81	ATIM-01. NIVOLUMAB AND BEVACIZUMAB FOR RECURRENT GLIOBLASTOMA; A TRANSLATIONAL TRIAL IN PROGRESS. Neuro-Oncology, 2019, 21, vi1-vi1.	1.2	0
82	T cell recognition of novel shared breast cancer antigens is frequently observed in peripheral blood of breast cancer patients. OncoImmunology, 2019, 8, e1663107.	4.6	9
83	Long-Term Exposure to Inflammation Induces Differential Cytokine Patterns and Apoptosis in Dendritic Cells. Frontiers in Immunology, 2019, 10, 2702.	4.8	20
84	Principles of adoptive T cell therapy in cancer. Seminars in Immunopathology, 2019, 41, 49-58.	6.1	141
85	Differential effects of corticosteroids and antiâ€TNF on tumorâ€specific immune responses: implications for the management of irAEs. International Journal of Cancer, 2019, 145, 1408-1413.	5.1	36
86	HER2 CAR-T Cells Eradicate Uveal Melanoma and T-cell Therapyâ€“Resistant Human Melanoma in IL2 Transgenic NOD/SCID IL2 Receptor Knockout Mice. Cancer Research, 2019, 79, 899-904.	0.9	84
87	The real-world impact of modern treatments on the survival of patients with metastatic melanoma. European Journal of Cancer, 2019, 108, 25-32.	2.8	47
88	Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy. JAMA Oncology, 2019, 5, 187.	7.1	295
89	Immunoprofiles of colorectal cancer from Lynch syndrome. OncoImmunology, 2019, 8, e1515612.	4.6	14
90	Personalized response-driven adjuvant therapy after combination ipilimumab and nivolumab in high-risk resectable stage III melanoma: PRADO trial.. Journal of Clinical Oncology, 2019, 37, TPS9605-TPS9605.	1.6	16

#	Article	IF	Citations
91	Assessment of extracellular matrix and tissue derived metabolites in a liquid biopsy for identifying endotypes of metastatic melanoma patients with differential response to immune checkpoint inhibitor treatment.. Journal of Clinical Oncology, 2019, 37, e14050-e14050.	1.6	0
92	Cancer immunotherapy in patients with brain metastases. Cancer Immunology, Immunotherapy, 2018, 67, 703-711.	4.2	15
93	Peptideâ€“MHC Class I Tetramers Can Fail To Detect Relevant Functional T Cell Clonotypes and Underestimate Antigen-Reactive T Cell Populations. Journal of Immunology, 2018, 200, 2263-2279.	0.8	87
94	Spontaneous T-cell responses against the immune check point programmed-death-ligand 1 (PD-L1) in patients with chronic myeloproliferative neoplasms correlate with disease stage and clinical response. OncoImmunology, 2018, 7, e1433521.	4.6	30
95	Development of anti-drug antibodies is associated with shortened survival in patients with metastatic melanoma treated with ipilimumab. OncoImmunology, 2018, 7, e1424674.	4.6	43
96	T-cell Responses in the Microenvironment of Primary Renal Cell Carcinomaâ€”Implications for Adoptive Cell Therapy. Cancer Immunology Research, 2018, 6, 222-235.	3.4	59
97	The inhibitory checkpoint, PD-L2, is a target for effector T cells: Novel possibilities for immune therapy. OncoImmunology, 2018, 7, e1390641.	4.6	33
98	Frequent adaptive immune responses against arginase-1. OncoImmunology, 2018, 7, e1404215.	4.6	27
99	Sorted peripheral blood cells identify CALR mutations in B- and T-lymphocytes. Leukemia and Lymphoma, 2018, 59, 973-977.	1.3	15
100	Non-invasive biomarkers derived from the extracellular matrix associate with response to immune checkpoint blockade (anti-CTLA-4) in metastatic melanoma patients. , 2018, 6, 152.		53
101	Durable Clinical Responses and Long-Term Follow-Up of Stage IIIâ€“IV Non-Small-Cell Lung Cancer (NSCLC) Patients Treated With IDO Peptide Vaccine in a Phase I Studyâ€”A Brief Research Report. Frontiers in Immunology, 2018, 9, 2145.	4.8	37
102	Adoptive cell therapy with tumor-infiltrating lymphocytes in patients with metastatic ovarian cancer: a pilot study. OncoImmunology, 2018, 7, e1502905.	4.6	80
103	Novel Strategies for Peptide-Based Vaccines in Hematological Malignancies. Frontiers in Immunology, 2018, 9, 2264.	4.8	19
104	The majority of patients with metastatic melanoma are not represented in pivotal phase III immunotherapy trials. European Journal of Cancer, 2017, 74, 89-95.	2.8	77
105	Dendritic cell vaccination in combination with docetaxel for patients with metastatic castration-resistant prostate cancer: A randomized phase II study. Cytotherapy, 2017, 19, 500-513.	0.7	58
106	Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncology, The, 2017, 18, 611-622.	10.7	428
107	Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model. Nature Communications, 2017, 8, 707.	12.8	123
108	PD-1+ Polyfunctional T Cells Dominate the Periphery after Tumor-Infiltrating Lymphocyte Therapy for Cancer. Clinical Cancer Research, 2017, 23, 5779-5788.	7.0	53

#	Article	IF	Citations
109	Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNÎ³ Signaling. Cancer Research, 2017, 77, 4562-4566.	0.9	39
110	Cancer immunotherapy in patients with preexisting autoimmune disorders. Seminars in Immunopathology, 2017, 39, 333-337.	6.1	31
111	Clinical Impact of the Number of Treatment Cycles in First-Line Docetaxel for Patients With Metastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer, 2017, 15, e281-e287.	1.9	5
112	Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma. Nature Communications, 2017, 8, 1738.	12.8	310
113	Indoleamine 2,3-dioxygenase and survivin peptide vaccine combined with temozolomide in metastatic melanoma. Stem Cell Investigation, 2017, 4, 77-77.	3.0	22
114	Real life outcome of advanced melanoma patients who discontinue pembrolizumab (PEMBRO) in the absence of disease progression.. Journal of Clinical Oncology, 2017, 35, 9539-9539.	1.6	4
115	Combination immunotherapy with IDO vaccine and PD-1 inhibitors in advanced NSCLC.. Journal of Clinical Oncology, 2017, 35, TPS2610-TPS2610.	1.6	6
116	Influence of ipilimumab on expanded tumour derived T cells from patients with metastatic melanoma. Oncotarget, 2017, 8, 27062-27074.	1.8	26
117	Preclinical development of tumor-infiltrating lymphocyte (TIL) based adoptive cell transfer (ACT) immunotherapy for patients with sarcoma and the potential benefit of anti-CD137 stimulation.. Journal of Clinical Oncology, 2017, 35, e14545-e14545.	1.6	0
118	Peptide vaccination against multiple myeloma using peptides derived from anti-apoptotic proteins: a phase I trial. Stem Cell Investigation, 2016, 3, 95-95.	3.0	16
119	The Danish Melanoma Database. Clinical Epidemiology, 2016, Volume 8, 543-548.	3.0	17
120	mRNA-transfected dendritic cell vaccine in combination with metronomic cyclophosphamide as treatment for patients with advanced malignant melanoma. OncoImmunology, 2016, 5, e1207842.	4.6	29
121	Safety, immune and clinical responses in metastatic melanoma patients vaccinated with a long peptide derived from indoleamine 2,3-dioxygenase in combination with ipilimumab. Cytotherapy, 2016, 18, 1043-1055.	0.7	45
122	PD-L1 peptide co-stimulation increases immunogenicity of a dendritic cell-based cancer vaccine. OncoImmunology, 2016, 5, e1202391.	4.6	33
123	CCL22-specific T Cells: Modulating the immunosuppressive tumor microenvironment. OncoImmunology, 2016, 5, e1238541.	4.6	56
124	Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen. Clinical Cancer Research, 2016, 22, 3734-3745.	7.0	234
125	Immune Monitoring Using mRNA-Transfected Dendritic Cells. Methods in Molecular Biology, 2016, 1428, 245-259.	0.9	3
126	Immunological correlates of treatment and response in stage IV malignant melanoma patients treated with Ipilimumab. OncoImmunology, 2016, 5, e1100788.	4.6	73

#	Article	IF	Citations
127	Predictors of Chemotherapy-Induced Toxicity and Treatment Outcomes in Elderly Versus Younger Patients With Metastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer, 2016, 14, e559-e568.	1.9	14
128	Large-scale detection of antigen-specific T cells using peptide-MHC-I multimers labeled with DNA barcodes. Nature Biotechnology, 2016, 34, 1037-1045.	17.5	279
129	Autocrine CCL19 blocks dendritic cell migration toward weak gradients of CCL21. Cytotherapy, 2016, 18, 1187-1196.	0.7	18
130	Large-Scale mRNA Transfection of Dendritic Cells by Electroporation in Continuous Flow Systems. Methods in Molecular Biology, 2016, 1428, 151-161.	0.9	1
131	Transfection of Tumor-Infiltrating T Cells with mRNA Encoding CXCR2. Methods in Molecular Biology, 2016, 1428, 261-276.	0.9	11
132	Interferonâ€Î± induces marked alterations in circulating regulatory T cells, <scp>NK</scp> cell subsets, and dendritic cells in patients with <scp>JAK</scp>2V617Fâ€positive essential thrombocythemia and polycythemia vera. European Journal of Haematology, 2016, 97, 83-92.	2.2	30
133	The controversial role of TNF in melanoma. OncoImmunology, 2016, 5, e1107699.	4.6	20
134	More tricks with tetramers: a practical guide to staining T cells with peptideâ€“<scp>MHC</scp> multimers. Immunology, 2015, 146, 11-22.	4.4	106
135	Design and validation of conditional ligands for <scp>HLAâ€B</scp>*08:01, <scp>HLAâ€B</scp>*15:01, <scp>HLAâ€B</scp>*35:01, and <scp>HLAâ€B</scp>*44:05. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2015, 87, 967-975.	1.5	21
136	Aberrant Expression of MHC Class II in Melanoma Attracts Inflammatory Tumor-Specific CD4+ T- Cells, Which Dampen CD8+ T-cell Antitumor Reactivity. Cancer Research, 2015, 75, 3747-3759.	0.9	93
137	Low-dose prednisolone in first-line docetaxel for patients with metastatic castration-resistant prostate cancer: Is there a clinical benefit?. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 494.e15-494.e20.	1.6	11
138	Tumor infiltrating lymphocyte therapy for ovarian cancer and renal cell carcinoma. Human Vaccines and Immunotherapeutics, 2015, 11, 2790-2795.	3.3	54
139	Indoleamine 2,3-dioxygenase vaccination. OncoImmunology, 2015, 4, e983770.	4.6	20
140	Antibody Stabilization of Peptideâ€“MHC Multimers Reveals Functional T Cells Bearing Extremely Low-Affinity TCRs. Journal of Immunology, 2015, 194, 463-474.	0.8	55
141	Successful treatment with Ipilimumab and Interleukin-2 in two patients with metastatic melanoma and systemic autoimmune disease. Cancer Immunology, Immunotherapy, 2014, 63, 1341-1346.	4.2	55
142	Spontaneous presence of FOXO3-specific T cells in cancer patients. OncoImmunology, 2014, 3, e953411.	4.6	4
143	Late development of splenic sarcoidosis-like lesions in a patient with metastatic melanoma and long-lasting clinical response to ipilimumab. OncoImmunology, 2014, 3, e954506.	4.6	56
144	Long-lasting Disease Stabilization in the Absence of Toxicity in Metastatic Lung Cancer Patients Vaccinated with an Epitope Derived from Indoleamine 2,3 Dioxygenase. Clinical Cancer Research, 2014, 20, 221-232.	7.0	118

#	Article	IF	Citations
145	Achievements and challenges of adoptive T cell therapy with tumor-infiltrating or blood-derived lymphocytes for metastatic melanoma: what is needed to achieve standard of care?. Cancer Immunology, Immunotherapy, 2014, 63, 1081-1091.	4.2	48
146	Simplified protocol for clinical-grade tumor-infiltrating lymphocyte manufacturing with use of the Wave bioreactor. Cytotherapy, 2014, 16, 1117-1120.	0.7	47
147	Effects of ipilimumab on expanded tumor-infiltrating lymphocytes in patients with stage IV malignant melanoma.. Journal of Clinical Oncology, 2014, 32, 3020-3020.	1.6	2
148	PD-L1 specific tumor infiltrating lymphocytes occur frequently in melanoma and HNSCC patients.. Journal of Clinical Oncology, 2014, 32, 11083-11083.	1.6	0
149	FDG PET scans as evaluation of clinical response to dendritic cell vaccination in patients with malignant melanoma. Cancer Immunology, Immunotherapy, 2013, 62, 17-25.	4.2	12
150	Depletion of T lymphocytes is correlated with response to temozolomide in melanoma patients. OncoImmunology, 2013, 2, e23288.	4.6	25
151	HLA-Restricted CTL That Are Specific for the Immune Checkpoint Ligand PD-L1 Occur with High Frequency in Cancer Patients. Cancer Research, 2013, 73, 1764-1776.	0.9	78
152	The immune checkpoint regulator PD-L1 is a specific target for naturally occurring CD4⁺T cells. OncoImmunology, 2013, 2, e23991.	4.6	52
153	Adoptive T-cell therapy (ACT) with TILs for metastatic melanoma: Clinical responses and durable persistence of anticancer responses in peripheral blood.. Journal of Clinical Oncology, 2013, 31, 3028-3028.	1.6	2
154	Phase I study of peptide vaccine targeting indeolamine 2,3 dioxygenase in metastatic lung cancer patients.. Journal of Clinical Oncology, 2013, 31, 8084-8084.	1.6	0
155	BRAF inhibition improves tumor recognition by the immune system. OncoImmunology, 2012, 1, 1476-1483.	4.6	82
156	Dissection of T-cell Antigen Specificity in Human Melanoma. Cancer Research, 2012, 72, 1642-1650.	0.9	137
157	Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase II trial. Cancer Immunology, Immunotherapy, 2012, 61, 1791-1804.	4.2	103
158	Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients. Journal of Translational Medicine, 2012, 10, 169.	4.4	134
159	Natural CD4+ T-Cell Responses against Indoleamine 2,3-Dioxygenase. PLoS ONE, 2012, 7, e34568.	2.5	43
160	Characterization of Spontaneous Immune Responses against Long Peptides Derived from Bcl-X(L) in Cancer Patients Using Elispot. Cells, 2012, 1, 51-60.	4.1	2
161	Comment on â€œAdoptive T-cell therapy for malignant melanoma patients with TILs obtained by ultrasound-guided needle biopsyâ€•by Gustav J. Ullenhag et al.. Cancer Immunology, Immunotherapy, 2012, 61, 747-747.	4.2	0
162	Bimodal ex vivo expansion of T cells from patients with head and neck squamous cell carcinoma: a prerequisite for adoptive cell transfer. Cytotherapy, 2011, 13, 822-834.	0.7	39

#	Article	IF	Citations
163	Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators. Blood, 2011, 117, 2200-2210.	1.4	101
164	High immunogenic potential of p53 mRNA-transfected dendritic cells in patients with primary breast cancer. Breast Cancer Research and Treatment, 2011, 125, 395-406.	2.5	41
165	Spontaneous Cytotoxic T-Cell Reactivity against Indoleamine 2,3-Dioxygenase-2. Cancer Research, 2011, 71, 2038-2044.	0.9	45
166	The Immune System Strikes Back: Cellular Immune Responses against Indoleamine 2,3-dioxygenase. PLoS ONE, 2009, 4, e6910.	2.5	64
167	Alterations in p53-specific T cells and other lymphocyte subsets in breast cancer patients during vaccination with p53-peptide loaded dendritic cells and low-dose interleukin-2. Vaccine, 2008, 26, 4716-4724.	3.8	25
168	Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkers. Cancer Immunology, Immunotherapy, 2007, 56, 1485-1499.	4.2	85
169	Spontaneous T-cell responses against peptides derived from the Taxol resistanceâ€“associated gene-3 (TRAG-3) protein in cancer patients. Cancer Immunology, Immunotherapy, 2005, 54, 219-228.	4.2	15
170	Vaccination with p53-peptide?pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study. Cancer Immunology, Immunotherapy, 2004, 53, 633-641.	4.2	100
171	Clinical application of dendritic cells in cancer vaccination therapy. Apmis, 2003, 111, 818-834.	2.0	41
172	Immune selection in murine tumors. Ph.d thesis. Acta Pathologica Microbiologica Et Immunologica Scandinavica - Supplementum, 2003, , 1-46.	0.2	0
173	High MHC class I expression correlates with slow growth in UVâ€induced skin carcinomas in hairless mice. Apmis, 1998, 106, 1101-1107.	2.0	2
174	Methylcholanthreneâ€induced sarcomas in nude mice have short induction times and relatively low levels of surface MHC class I expression. Apmis, 1996, 104, 629-639.	2.0	35
175	Chemically induced sarcomas from nude mice are more immunogenic than similar sarcomas from congenic normal mice. European Journal of Immunology, 1996, 26, 1844-1850.	2.9	62
176	Expression of Î²2-microglobulin by premalignant epithelium. Apmis, 1993, 101, 529-536.	2.0	14